Clinical trial
Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic…
NCT00302081 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00302081 |
|---|---|
| Title | Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548) |
| Official title | Comparison of Three Regimens of PEG-Intron and Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Integrated Therapeutics Group Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Biological, Drug |
| Interventions | peginterferon alfa-2b (SCH 54031), ribavirin (SCH 18908) |
| Enrollment | 696 |
| Start date | Aug 1, 2003 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Mar 13, 2006 |
| Last update posted | Apr 5, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: